$3.87
-0.13 (-3.25%)
Open$3.96
Previous Close$4.00
Day High$4.05
Day Low$3.76
52W High$54.97
52W Low$3.25
Volume—
Avg Volume776.5K
Market Cap148.30M
P/E Ratio—
EPS$-2.17
SectorBiotechnology
Analyst Ratings
Hold
17 analysts
Price Target
+547.5% upside
Current
$3.87
$3.87
Target
$25.06
$25.06
$14.18
$25.06 avg
$26.23
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 242.99M | 245.23M | 253.21M |
| Net Income | -48,406,908 | -45,232,819 | -47,387,261 |
| Profit Margin | -19.9% | -18.5% | -18.7% |
| EBITDA | -47,660,000 | -53,758,331 | -46,826,478 |
| Free Cash Flow | -27,352,313 | -27,764,891 | -38,614,891 |
| Rev Growth | +24.0% | +24.2% | +22.9% |
| Debt/Equity | 0.34 | 0.34 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |